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America, and Japan) (6). The natural 
habitats of M. wolfii include moldy 
grass in silage, and infected animals 
might inhale spores from contami-
nated silage or acquire them through 
digestive tract ulcerations after in-
gestion of semen (4). Thus, possible 
transmission routes of Mortierella 
sp. in this patient include airborne 
exposure to mulch or ingestion of 
contaminated imported food during 
pressure-selection azole prophylaxis 
and inflammatory bowel disease. 
After being ingested or inhaled, this 
weakly virulent mold must have re-
mained quiescent until a few months 
before HSCT. We suspect that it was 
responsible for the necrotic cavitary 
pneumonia for which no fungus was 
identified before transplant. M. wolfii 
eventually emerged during a pro-
found iatrogenic neutropenic period 
(1). Because death partly correlates 
with dissemination, preemptive and 
adequate antifungal treatment is of 
utmost importance in mucormyco-
sis. In this patient, who died 11 days 
after ICU admission, past anaphy-
laxis precluded prompt initiation of 
a lipid-based formulation of AmB, 
which remains the best choice for 
treating invasive mucormycosis (7). 
Posaconazole, a second-choice drug, 
has shown efficacy in CGD patients 
who had invasive mucormycosis re-
sistant to first-line treatment (8). Al-
logeneic donor–matched HSCT has 
a curative potential in CGD patients 
with refractory fungal infections (9). 
Several other authors have pointed 
to the emergence of rare new fungi 
in CGD, as well as reclassification 
of misdiagnosed fungi, identified by 
sequence-based analysis (10).
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To The Editor: Woodrats (Neo-
toma spp.) are natural hosts of White-
water Arroyo virus (WWAV) and other 
Tacaribe serocomplex viruses (family 
Arenaviridae) in the western United 
States and northern Mexico (1). The re-
sults of a previous study (2) suggested 
that WWAV or Tacaribe serocomplex 
viruses antigenically closely related to 
WWAV are etiologic agents of severe 
febrile illnesses in humans in the Unit-
ed States. We note that Junín virus and 
other South American Tacaribe sero-
complex viruses are etiologic agents of 
hemorrhagic fever in humans (3).
To further our knowledge of the 
epidemiology of the North American 
Tacaribe serocomplex viruses, we 
tested serum samples from hospital-
ized persons in a study of thrombo-
cytopenic febrile illnesses that mim-
icked hantavirus pulmonary syndrome 
for IgG against arenaviruses. The 173 
study participants were hospitalized 
during 1993–2001 in Arizona and New 
Mexico, United States. The study pro-
tocol was approved by the University 
of New Mexico Human Research Re-
view Committee and the Navajo Na-
tion Institutional Review Board. Ages 
of the study participants ranged from 9 
to 86 years (mean 40 years). Virtually 
all serum samples were acute-phase 
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specimens, and a specific diagnosis 
was achieved for only 55 (31.8%) of 
the 173 study participants.
Serum samples were tested for 
IgG against WWAV, Amaparí virus 
(AMAV), an arenavirus that is anti-
genically closely related to the Tacaribe 
serocomplex viruses known to cause 
hemorrhagic fever (4), and lymphocyt-
ic choriomeningitis virus (LCMV), the 
prototypical arenavirus and member of 
the Lassa–lymphocytic choriomeningi-
tis serocomplex, by using an ELISA. 
(5). Briefly, we tested serial 4-fold di-
lutions (1:80–1:5,120) of each sample 
and compared results with results for 
negative control antigens. The adjusted 
optical density (AOD) of a sample-
antigen reaction was the OD associated 
with the test antigen minus the OD as-
sociated with the corresponding control 
antigen. A sample was considered posi-
tive if the AOD at 1:80 was ≥0.250, the 
AOD at 1:320 was ≥0.250, and the sum 
of the AOD for the series of 4-fold dilu-
tions was ≥0.750. The criteria for posi-
tivity were based on results of ELISA 
for serum samples from febrile persons 
who did not participate in this study and 
were negative for IgG against WWAV, 
AMAV, and LCMV.
The IgG titer against a test antigen 
in a positive sample was the reciprocal 
of the highest dilution for which the 
AOD was ≥0.250. Titers <320 were 
considered to be 160 in comparisons of 
titers for WWAV, AMAV, and LCMV 
in individual samples. The apparent 
homologous virus in a positive sample 
was the virus associated with the high-
est titer if the absolute value of the dif-
ferences between the highest titer and ti-
ters for the 2 other viruses were ≥4-fold.
IgG against WWAV was found in 
acute-phase samples from 8 (4.6%) of 
the 173 study participants. None of the 
173 study participants were positive 
for IgG against AMAV or LCMV. The 
IgG titers against WWAV in the posi-
tive samples were 320 (n = 1), 1,280 (n 
= 3), and ≥5,120 (n = 4). WWAV was 
the apparent homologous virus in the 
7 persons with antibody titers ≥1,280. 
The apparent homologous virus in the 
person with the titer of 320 could not 
be determined from ELISA data. The 
presence of IgG against WWAV in 
acute-phase serum samples (all col-
lected within 10 days of illness onset) 
implied past infection with WWAV or 
an arenavirus antigenically closely re-
lated to WWAV.
The state of residence (2 from 
Arizona, 6 from New Mexico), sex ra-
tio (4 male patients:4 female patients), 
and mean age (36 years, range 16–47 
years) of antibody-positive persons re-
flected the characteristics of the entire 
study population. The clinical features 
in each of the antibody-positive per-
sons included fever, headache, my-
algia, and thrombocytopenia. The di-
agnoses given for these persons were 
acute parvovirus infection (n = 1) by 
IgM assay, adult respiratory distress 
syndrome (n = 1) by clinical progres-
sion, and not determined (n = 6).
The results of this study indicate 
that a small fraction of the adult popu-
lation in the southwestern United States 
has been infected with North American 
Tacaribe serocomplex virus(es). We 
note that the dominant epitopes in ELI-
SA for IgG against arenaviruses are as-
sociated with the viral nucleocapsid (N) 
protein, and that amino acid sequence 
of the N protein of WWAV and amino 
acid sequences of N proteins of other 
Tacaribe arenaviruses from Arizona or 
New Mexico showed differences as 
high as 15.1% in a previous study (1).
It might be the case that human 
IgG against some Tacaribe sero-
complex viruses in the southwestern 
United States does not react strongly 
against WWAV in ELISA. If so, the 
true prevalence of antibody against 
North American Tacaribe serocomplex 
viruses in this study might be >4.6%. 
Accordingly, future work should in-
clude development of broadly reactive 
assays for detection of human IgM 
and human IgG against North Ameri-
can Tacaribe serocomplex viruses, 
including those associated with wild 
rodents in Mexico (6,7).
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